Several possible studies
Story checked
Marios Georgakis: Why Did Two Major Clinical Trials for Heart Disease Fail? (opens in a new tab)
erictopol.substack.com · 2026-09-14
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Marios Georgakis: Why Did Two Major Clinical Trials for Heart Disease Fail?
erictopol.substack.com · 2026-09-14
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedTwo major placebo-controlled randomized trials, ZEUS and HORIZON, were announced by press release and indicated failure to achieve their primary endpoint.View evidenceHide evidence
As stated2 major trials
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedZEUS tested an interleukin-6 (IL-6) blocker, while HORIZON tested a drug to lower Lp(a).View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedThe article asks whether cardiovascular drug development is running out of easy wins, or whether the trial results and reasons for failure are more complicated than that.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedThe author argues that the field has not been maxxed out and says he and Marios Georgakis remain optimistic that there is still substantial room for progress in heart-disease treatments.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe article frames heart disease as the number one global killer for both men and women despite progress made to date.View evidenceHide evidence
As statednumber one global killer
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref · 15 candidate papers
Targeting Inflammation in Chronic Kidney Disease: Pathophysiological Insights and Emerging Therapeutic Strategies.
Journal of Clinical Medicine · 2026 · PubMed
From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?
Cardiovascular Research · 2021 · PubMed, Crossref
From Selye to ZEUS: inflammation as the adaptation syndrome's hidden machinery.
European Journal of Preventive Cardiology · 2026 · PubMed
An Inappropriate Primary Endpoint
JACC: Cardiovascular Interventions · 2021 · Crossref
A quantitative method to estimate free interleukin-6 among patients treated with the interleukin-6 ligand inhibitor ziltivekimab: comparison to C-reactive protein with implications for the ZEUS, HERMES, and ARTEMIS cardiovascular outcomes trials.
Atherosclerosis · 2026 · PubMed, Crossref
And 10 more candidates considered.